Hepatitis C Treatment by Nonspecialist Providers in the Direct-acting Antiviral Era
- 3 June 2021
- journal article
- research article
- Published by Wolters Kluwer Health in Medical Care
- Vol. 59 (9) , 795-800
Abstract
Background: Hepatitis C virus (HCV) remains under-treated in the United States and treatment by nonspecialist providers can expand access. We compare HCV treatment provision and treatment completion between nonspecialist and specialist providers. Methods: This retrospective study used claims data from the Healthcare Cost Institute from 2013 to 2017. We identified providers who prescribed HCV therapy between 2013 and 2017, and patients enrolled in private insurance or Medicare Advantage who had pharmacy claims for HCV treatment. We measured HCV treatment completion, determined based on prescription fills for the minimum expected duration of the antiviral regimen. Using propensity score–weighted regression, we compared the likelihood of early treatment discontinuation by the type of treating provider. Results: The number of providers prescribing HCV treatment peaked in 2015 and then declined. The majority were gastroenterologists, although the proportion of general medicine providers increased to 17% by 2017. Among the 23,463 patients analyzed, 1008 (4%) discontinued before the expected minimum duration. In the propensity score–weighted analysis, patients treated by general medicine physicians had similar odds of treatment discontinuation compared with those treated by gastroenterologists [odds ratio (OR)=1.00, 95% confidence interval (CI): 0.99–1.01, P=0.45]. Results were similar when comparing gastroenterologists to nonphysician providers (OR=1.00, 95% CI: 0.99–1.01, P=0.53) and infectious diseases specialists (OR=1.00, 95% CI: 0.99–1.01, P=0.71). Conclusions: HCV treatment providers remain primarily gastroenterologists, even in the current simplified treatment era. Patients receiving treatment from general medicine or nonphysician providers had a similar likelihood of treatment completion, suggesting that removing barriers to the scale-up of treatment by nonspecialists may help close treatment gaps for hepatitis C.Keywords
This publication has 29 references indexed in Scilit:
- Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care settingInternational Journal of Drug Policy, 2017
- Provider Workforce Assessment in a Rural Hepatitis C EpidemicJournal of Primary Care & Community Health, 2014
- Methods for Constructing and Assessing Propensity ScoresHealth Services Research, 2014
- A tutorial on propensity score estimation for multiple treatments using generalized boosted modelsStatistics in Medicine, 2013
- Public Health Detailing of Primary Care Providers: New York City’s Experience, 2003–2010American Journal of Public Health, 2012
- Management of Hepatitis C Antiviral Therapy Adverse EffectsCurrent Hepatitis Reports, 2010
- Expanding Access to Hepatitis C Virus Treatment—Extension for Community Healthcare Outcomes (ECHO) Project: Disruptive Innovation in Specialty Care†Hepatology, 2010
- Doubly Robust Estimation in Missing Data and Causal Inference ModelsBiometrics, 2005
- Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative DataMedical Care, 2005
- Propensity Score Estimation With Boosted Regression for Evaluating Causal Effects in Observational Studies.Psychological Methods, 2004